These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 29127931)

  • 1. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
    He H; Wang W; Lyu J; Zheng J; Guo L; An X; Fan Y; Ma X
    J Psychiatr Res; 2018 Jan; 96():247-259. PubMed ID: 29127931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis.
    Wagner G; Schultes MT; Titscher V; Teufer B; Klerings I; Gartlehner G
    J Affect Disord; 2018 Mar; 228():1-12. PubMed ID: 29197738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.
    Deardorff WJ; Grossberg GT
    Expert Opin Pharmacother; 2014 Dec; 15(17):2525-42. PubMed ID: 25224953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vortioxetine for depression in adults.
    Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L
    J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
    Llorca PM; Lançon C; Brignone M; Rive B; Salah S; Ereshefsky L; Francois C
    Curr Med Res Opin; 2014 Dec; 30(12):2589-606. PubMed ID: 25249164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
    Sambunaris A; Bose A; Gommoll CP; Chen C; Greenberg WM; Sheehan DV
    J Clin Psychopharmacol; 2014 Feb; 34(1):47-56. PubMed ID: 24172209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
    Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
    J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
    Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
    J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
    Nishimura A; Aritomi Y; Sasai K; Kitagawa T; Mahableshwarkar AR
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out.
    Citrome L
    Int J Clin Pract; 2015 Feb; 69(2):151-5. PubMed ID: 25627335
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
    Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
    Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y; Trivedi MH
    J Clin Psychiatry; 2015 May; 76(5):583-91. PubMed ID: 26035186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant.
    Atsou K; Ereshefsky L; Brignone M; Danchenko N; Diamand F; Mucha L; Touya M; Becker R; François C
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):29-42. PubMed ID: 33307885
    [No Abstract]   [Full Text] [Related]  

  • 16. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
    Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
    J Psychiatry Neurosci; 2015 May; 40(3):174-86. PubMed ID: 25350320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
    Inoue T; Nishimura A; Sasai K; Kitagawa T
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Croft HA; Pomara N; Gommoll C; Chen D; Nunez R; Mathews M
    J Clin Psychiatry; 2014 Nov; 75(11):e1291-8. PubMed ID: 25470094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
    Berhan A; Barker A
    BMC Psychiatry; 2014 Sep; 14():276. PubMed ID: 25260373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.